TY - JOUR
T1 - Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma
AU - Iser, Stephanie
AU - Hintermair, Sarah
AU - Varga, Alexander
AU - Çelik, Ali
AU - Sayan, Muhammet
AU - Kankoç, Aykut
AU - Akyürek, Nalan
AU - Öğüt, Betül
AU - Bertoglio, Pietro
AU - Capozzi, Enrico
AU - Solli, Piergiorgio
AU - Ventura, Luigi
AU - Waller, David
AU - Weber, Michael
AU - Stubenberger, Elisabeth
AU - Ghanim, Bahil
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/12/24
Y1 - 2023/12/24
N2 - Evoked from asbestos-induced inflammation, pleural mesothelioma represents a fatal diagnosis. Therapy ranges from nihilism to aggressive multimodality regimens. However, it is still unclear who ultimately benefits from which treatment. We aimed to re-challenge inflammatory-related biomarkers' prognostic value in times of modern immune-oncology and lung-sparing surgery. The biomarkers (leukocytes, hemoglobin, platelets, neutrophils, lymphocytes, monocytes, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), C-reactive protein (CRP)) and clinical characteristics (age, sex, histology, therapy) of 98 PM patients were correlated to overall survival (OS). The median OS was 19.4 months. Significant OS advantages (Log-Rank) were observed in multimodal treatment vs. others (26.1 vs. 7.2 months,
p < 0.001), surgery (pleurectomy/decortication) vs. no surgery (25.5 vs. 3.8 months,
p < 0.001), a high hemoglobin level (cut-off 12 g/dL, 15 vs. 24.2 months,
p = 0.021), a low platelet count (cut-off 280 G/L, 26.1 vs. 11.7 months,
p < 0.001), and a low PLR (cut-off 194.5, 25.5 vs. 12.3 months,
p = 0.023). Histology (epithelioid vs. non-epithelioid,
p = 0.002), surgery (
p = 0.004), CRP (cut-off 1 mg/dL,
p = 0.039), and platelets (
p = 0.025) were identified as independent prognostic variables for this cohort in multivariate analysis (Cox regression, covariates: age, sex, histology, stage, CRP, platelets). Our data verified the previously shown prognostic role of systemic inflammatory parameters in patients treated with lung-sparing surgery within multimodality therapy.
AB - Evoked from asbestos-induced inflammation, pleural mesothelioma represents a fatal diagnosis. Therapy ranges from nihilism to aggressive multimodality regimens. However, it is still unclear who ultimately benefits from which treatment. We aimed to re-challenge inflammatory-related biomarkers' prognostic value in times of modern immune-oncology and lung-sparing surgery. The biomarkers (leukocytes, hemoglobin, platelets, neutrophils, lymphocytes, monocytes, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), C-reactive protein (CRP)) and clinical characteristics (age, sex, histology, therapy) of 98 PM patients were correlated to overall survival (OS). The median OS was 19.4 months. Significant OS advantages (Log-Rank) were observed in multimodal treatment vs. others (26.1 vs. 7.2 months,
p < 0.001), surgery (pleurectomy/decortication) vs. no surgery (25.5 vs. 3.8 months,
p < 0.001), a high hemoglobin level (cut-off 12 g/dL, 15 vs. 24.2 months,
p = 0.021), a low platelet count (cut-off 280 G/L, 26.1 vs. 11.7 months,
p < 0.001), and a low PLR (cut-off 194.5, 25.5 vs. 12.3 months,
p = 0.023). Histology (epithelioid vs. non-epithelioid,
p = 0.002), surgery (
p = 0.004), CRP (cut-off 1 mg/dL,
p = 0.039), and platelets (
p = 0.025) were identified as independent prognostic variables for this cohort in multivariate analysis (Cox regression, covariates: age, sex, histology, stage, CRP, platelets). Our data verified the previously shown prognostic role of systemic inflammatory parameters in patients treated with lung-sparing surgery within multimodality therapy.
UR - http://www.scopus.com/inward/record.url?scp=85182202083&partnerID=8YFLogxK
U2 - 10.3390/cancers16010093
DO - 10.3390/cancers16010093
M3 - Journal article
C2 - 38201520
SN - 2072-6694
VL - 16
SP - 93
JO - Cancers
JF - Cancers
IS - 1
M1 - 93
ER -